Amneal Pharmaceuticals (AMRX) Stock Forecast, Price Target & Predictions
AMRX Stock Forecast
Amneal Pharmaceuticals stock forecast is as follows: an average price target of $9.00 (represents a 8.17% upside from AMRX’s last price of $8.32) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
AMRX Price Target
The average price target for Amneal Pharmaceuticals (AMRX) is $9.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $4.00. This represents a potential 8.17% upside from AMRX's last price of $8.32.
AMRX Analyst Ratings
According to 3 Wall Street analysts, Amneal Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for AMRX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Amneal Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | David Amsellem | Piper Sandler | - | - | 32.69% | 32.21% |
| Oct 02, 2024 | Les Sulewski | Truist Financial | - | - | 37.93% | 44.23% |
| Oct 01, 2024 | Les Sulewski | Truist Financial | - | - | 14.94% | 20.19% |
| May 03, 2024 | Les Sulewski | Truist Financial | - | - | 33.14% | 8.17% |
| Mar 21, 2024 | David Amsellem | Piper Sandler | - | - | 27.19% | -3.85% |
| Aug 08, 2022 | Goldman Sachs | - | - | 24.22% | -51.92% |
The latest Amneal Pharmaceuticals stock forecast, released on Nov 11, 2024 by David Amsellem from Piper Sandler, set a price target of $11.00, which represents a 32.69% increase from the stock price at the time of the forecast ($8.29), and a 32.21% increase from AMRX last price ($8.32).
Amneal Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 3 | 5 |
| Avg Price Target | $11.00 | $11.00 | $10.00 |
| Last Closing Price | $8.32 | $8.32 | $8.32 |
| Upside/Downside | 32.21% | 32.21% | 20.19% |
In the current month, the average price target of Amneal Pharmaceuticals stock is $11.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 32.21% increase as opposed to Amneal Pharmaceuticals's last price of $8.32. This month's average price target is down 0.00% compared to last quarter, and up 10.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 11, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 13, 2024 | Barclays | Overweight | Overweight | Hold |
| Aug 08, 2022 | Goldman Sachs | Buy | Buy | Hold |
Amneal Pharmaceuticals's last stock rating was published by Piper Sandler on Nov 11, 2024. The company gave AMRX a "Overweight" rating, the same as its previous rate.
Amneal Pharmaceuticals Financial Forecast
Amneal Pharmaceuticals Revenue Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $616.98M | $620.04M | $557.54M | $609.76M | $497.63M | $493.11M | $498.53M | $446.12M | $275.19M | $259.87M |
| Avg Forecast | $686.79M | $703.74M | $690.23M | $657.52M | $619.00M | $630.67M | $602.60M | $589.50M | $561.04M | $535.91M | $438.32M | $411.29M | $573.58M | $334.17M | $185.62M |
| High Forecast | $688.38M | $709.00M | $693.55M | $660.68M | $621.97M | $637.60M | $605.49M | $707.40M | $673.24M | $643.09M | $525.98M | $493.55M | $688.30M | $401.01M | $222.75M |
| Low Forecast | $685.20M | $696.43M | $685.73M | $653.24M | $614.96M | $618.87M | $598.67M | $471.60M | $448.83M | $428.73M | $350.65M | $329.03M | $458.87M | $267.34M | $148.50M |
| # Analysts | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 14 | 16 | 11 | 20 | 18 | 18 | 12 | 18 |
| Surprise % | - | - | - | - | - | 0.98% | 1.03% | 0.95% | 1.09% | 0.93% | 1.13% | 1.21% | 0.78% | 0.82% | 1.40% |
Amneal Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 2 analysts is $619.00M, with a low forecast of $614.96M, and a high forecast of $621.97M. AMRX's average Quarter revenue forecast represents a 0.33% increase compared to the company's last Quarter revenue of $616.98M (Dec 23).
Amneal Pharmaceuticals EBITDA Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 14 | 16 | 11 | 20 | 18 | 18 | 12 | 18 |
| EBITDA | - | - | - | - | - | $14.19M | $135.55M | $98.67M | $135.25M | $82.28M | $96.50M | $104.88M | $35.84M | $87.70M | $57.02M |
| Avg Forecast | $106.98M | $109.62M | $107.51M | $102.42M | $111.46M | $98.23M | $93.86M | $101.32M | $102.14M | $92.11M | $85.78M | $82.63M | $43.80M | $103.18M | $40.73M |
| High Forecast | $107.22M | $110.44M | $108.03M | $102.91M | $133.75M | $99.31M | $94.31M | $121.59M | $122.57M | $110.53M | $102.93M | $99.16M | $52.57M | $123.81M | $48.88M |
| Low Forecast | $106.73M | $108.48M | $106.81M | $101.75M | $89.16M | $96.40M | $93.25M | $81.06M | $81.71M | $73.69M | $68.62M | $66.10M | $35.04M | $82.54M | $32.59M |
| Surprise % | - | - | - | - | - | 0.14% | 1.44% | 0.97% | 1.32% | 0.89% | 1.13% | 1.27% | 0.82% | 0.85% | 1.40% |
2 analysts predict AMRX's average Quarter EBITDA for Mar 24 to be $111.46M, with a high of $133.75M and a low of $89.16M. This is 685.29% upper than Amneal Pharmaceuticals's previous annual EBITDA (Dec 23) of $14.19M.
Amneal Pharmaceuticals Net Income Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 14 | 16 | 11 | 20 | 18 | 18 | 12 | 18 |
| Net Income | - | - | - | - | - | $-98.65M | $9.68M | $-10.09M | $-5.86M | $-6.46M | $6.71M | $115.07M | $-47.88M | $51.53M | $37.45M |
| Avg Forecast | $43.35M | $49.54M | $40.87M | $42.73M | $-2.81M | $21.68M | $39.33M | $-2.55M | $-3.34M | $-2.32M | $5.96M | $90.66M | $-58.52M | $60.63M | $26.75M |
| High Forecast | $46.45M | $55.74M | $41.13M | $43.00M | $-2.25M | $24.77M | $39.57M | $-2.04M | $-2.67M | $-1.86M | $7.15M | $108.79M | $-46.82M | $72.76M | $32.10M |
| Low Forecast | $37.16M | $43.35M | $40.53M | $42.37M | $-3.37M | $21.49M | $38.99M | $-3.06M | $-4.01M | $-2.79M | $4.77M | $72.53M | $-70.23M | $48.50M | $21.40M |
| Surprise % | - | - | - | - | - | -4.55% | 0.25% | 3.95% | 1.75% | 2.78% | 1.13% | 1.27% | 0.82% | 0.85% | 1.40% |
Amneal Pharmaceuticals's average Quarter net income forecast for Dec 23 is $21.68M, with a range of $21.49M to $24.77M. AMRX's average Quarter net income forecast represents a 123.87% increase compared to the company's last Quarter net income of $9.68M (Sep 23).
Amneal Pharmaceuticals SG&A Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 14 | 16 | 11 | 20 | 18 | 18 | 12 | 18 |
| SG&A | - | - | - | - | - | $109.00M | $113.01M | $102.10M | $102.16M | $98.67M | $90.73M | $77.98M | $84.44M | $25.12M | $26.94M |
| Avg Forecast | $120.44M | $123.41M | $121.04M | $115.30M | $128.57M | $110.59M | $105.67M | $116.88M | $93.16M | $106.25M | $80.65M | $61.44M | $103.20M | $29.55M | $19.24M |
| High Forecast | $120.71M | $124.33M | $121.62M | $115.86M | $154.28M | $111.81M | $106.18M | $140.26M | $111.79M | $127.51M | $96.77M | $73.72M | $123.84M | $35.46M | $23.09M |
| Low Forecast | $120.16M | $122.13M | $120.25M | $114.55M | $102.85M | $108.52M | $104.98M | $93.50M | $74.52M | $85.00M | $64.52M | $49.15M | $82.56M | $23.64M | $15.39M |
| Surprise % | - | - | - | - | - | 0.99% | 1.07% | 0.87% | 1.10% | 0.93% | 1.13% | 1.27% | 0.82% | 0.85% | 1.40% |
Amneal Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $128.57M, based on 2 Wall Street analysts, with a range of $102.85M to $154.28M. The forecast indicates a 17.95% rise compared to AMRX last annual SG&A of $109.00M (Dec 23).
Amneal Pharmaceuticals EPS Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 14 | 16 | 11 | 20 | 18 | 18 | 12 | 18 |
| EPS | - | - | - | - | - | $-0.40 | $0.06 | $-0.07 | $-0.04 | $-0.04 | $0.05 | $0.78 | $-0.37 | $0.45 | $0.33 |
| Avg Forecast | $0.14 | $0.16 | $0.13 | $0.14 | $0.09 | $0.07 | $0.13 | $1.43 | $1.95 | $1.43 | $0.16 | $0.07 | $0.22 | $0.20 | $0.10 |
| High Forecast | $0.15 | $0.18 | $0.13 | $0.14 | $0.09 | $0.08 | $0.13 | $1.44 | $1.97 | $1.43 | $0.19 | $0.09 | $0.26 | $0.24 | $0.12 |
| Low Forecast | $0.12 | $0.14 | $0.13 | $0.14 | $0.09 | $0.07 | $0.13 | $1.42 | $1.94 | $1.43 | $0.13 | $0.06 | $0.18 | $0.16 | $0.08 |
| Surprise % | - | - | - | - | - | -5.71% | 0.47% | -0.05% | -0.02% | -0.03% | 0.31% | 11.14% | -1.68% | 2.24% | 3.26% |
According to 4 Wall Street analysts, Amneal Pharmaceuticals's projected average Quarter EPS for Dec 23 is $0.07, with a low estimate of $0.07 and a high estimate of $0.08. This represents a 16.67% increase compared to AMRX previous annual EPS of $0.06 (Sep 23).
Amneal Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PROC | Procaps Group | - | - | 800.90% | |
| IRWD | Ironwood Pharmaceuticals | - | - | 249.40% | Buy |
| ASRT | Assertio | - | - | 196.91% | Buy |
| DVAX | Dynavax | - | - | 98.22% | Buy |
| EOLS | Evolus | - | - | 84.05% | Buy |
| AMPH | Amphastar Pharmaceuticals | - | - | 48.15% | Buy |
| ANIP | ANI Pharmaceuticals | - | - | 41.42% | Buy |
| COLL | Collegium Pharmaceutical | - | - | 33.18% | Buy |
| ALKS | Alkermes | - | - | 31.34% | Hold |
| NBIX | Neurocrine Biosciences | - | - | 17.88% | Buy |
| ITCI | Intra-Cellular Therapies | - | - | 10.59% | Buy |
| AMRX | Amneal Pharmaceuticals | - | - | 8.17% | Buy |
| DCPH | Deciphera Pharmaceuticals | - | - | 2.85% | Hold |
| LFCR | Lifecore Biomedical | - | - | -6.88% | Buy |
| PAHC | Phibro Animal Health | - | - | -21.42% | Buy |
| AGRX | Agile Therapeutics | - | - | -33.77% | Buy |